Skip to content

Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02452892
Enrollment
122
Registered
2015-05-25
Start date
2015-09-30
Completion date
2016-10-31
Last updated
2017-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Depressive Disorder, Depressive Disorder, Major, Depressive Disorder, Treatment-resistant

Keywords

Depression, Major depression, Low-field magnetic stimulation, LFMS

Brief summary

The purpose of this study is to compare the relative effectiveness of 20 and 60 minutes of Low-Field Magnetic Stimulation in relieving symptoms in patients with major depression who are treatment resistant.

Detailed description

The primary objective of this study: * To compare the relative efficacy, as measured by a change in the 6-item Hamilton Rating Scale for Depression (HAM-D6), of 20 and 60 minutes of LFMS compared to sham (placebo) in subjects with treatment resistant depression (TRD). Secondary objectives: * To determine if subjects with TRD may respond to 120 minutes of LFMS. * To determine the persistence of response to LFMS therapy during the observation period. * To evaluate the safety and tolerability of LFMS.

Interventions

DEVICELFMS

Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.

Sponsors

Tal Medical, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

(Key) * Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) criteria for Major Depressive Disorder (MDD), as determined by psychiatric evaluation. * Has TRD of the current MDE, as assessed at the site by the Massachusetts General Hospital/Antidepressant Treatment Response Questionnaire (MGH/ATRQ). * On an adequate dose of one antidepressant therapy (ADT) for at least eight weeks prior to the screening visit (Visit 1). The ADT dose must be stable for at least four weeks prior to the screening visit (Visit 1). Subjects must be willing to remain on the same stable dose of ADT upon signing the informed consent form until the end of the treatment observation period (end of Week 2) and, where possible, to the end of study participation

Exclusion criteria

(Key) * Have failed four or more lifetime adequate ADT treatment regimens (including the ongoing ADT for the current MDE). * Have been treated with adjunctive antipsychotic medication with an antidepressant for at least two weeks during the current depressive episode. * Are deemed to be at significant risk for suicidal behavior * Are unable to lie on their back for the duration of study treatment * Have a lifetime history of: 1. Delirium, dementia, amnestic, or other cognitive disorder; 2. Schizophrenia or any psychotic disorder, based on the Structured Clinical Interview for DSM-5 Axis I Disorders Patient Edition (SCID-I/P); 3. Bipolar I or II disorder, based on the SCID-I/P. * Have a current DSM-5 diagnosis at the screening visit (Visit 1) of: 1. An eating disorder active within the 12 months prior to the screening visit (Visit 1); 2. Comorbid anxiety disorders that predominate over MDD, as assessed by the investigator; 3. Alcohol or substance use disorder active within the 12 months prior to the screening visit (Visit 1); 4. Clinically significant DSM-5 Axis II disorder. * Have ever received electroconvulsive therapy, vagal nerve stimulation, deep brain stimulation or repetitive transcranial magnetic stimulation. * Have a non-removable programmable device or appliance such as cardiac pacemakers or cochlear implants. * Have any non-removable ferromagnetic implants, or conductive or other magnetic sensitive materials present in the head or neck . * Have a lifetime history of seizures or clinically significant electroencephalography abnormalities. A history of childhood febrile seizures is permitted.

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline to ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score.Week 1 Day 4Hamilton Rating Scales for Depression were designed to measure the severity of depressive symptoms in subjects with primary depressive illness. HAM-D6 is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 and all others are scored 0 to 4. Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline: mean score at Week 1 Day 4 minus mean score at baseline. Week 1 Day 4 : Change from baseline to the end of the efficacy period ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) total score .Responders at Day 4 will be defined as those subjects who achieve a decrease in HAM-D6 total score of 50% or more compared to baseline (Day 1, Week 1). All other subjects will be deemed to be non-responders at Day 4. Each patient's total score is his/her own reference for determining a decrease of 50% or more.

Secondary

MeasureTime frameDescription
Change From Day 4 in HAM-D6 Total Score at Day 11 for Week 1 Non-responders: Response to 120 Minutes LFMSDay 11 (Week 2)Hamilton Rating Scales for Depression were designed to measure the severity of depressive symptoms in subjects with primary depressive illness. HAM-D6 is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 and all others are scored 0 to 4. Total score ranges from 0 to 22; higher score indicates more depression. Change from Day 11: mean score at Week 2 Day 11 minus mean score at Day 4. To determine if subjects with TRD who are non-responders to 0, 20 or 60 minutes of LFMS on Day 4 may respond to 120 minutes of LFMS at the end of Day 11. Responders will be defined as those subjects who achieve a decrease in HAM-D6 total score of 50% or more compared to baseline (Day 1, Week 1). All other subjects will be deemed to be non-responders. Each patient's total score is his/her own reference for determining a decrease of 50% or more.
Day 4 Responders: Persistence of Effect Based on Pre-specified HAM-D6 Total ScoreDay 42To determine the persistence of response to LFMS therapy during a four-week follow-up period in subjects who were responders at Day 4. Persistence of response was achieved if during Week 2 post baseline visits and follow-up visits subjects' 6-item Hamilton Rating Scale for Depression (HAM-D6) total scores were lower than or equal to 50% of the baseline ( Day1 Week1) scores. Non-responder imputation method was used where missing post-baseline dichotomous (yes or no) were imputed as non-responder. Logistic regression model used to compare treatment groups for each visit, where the model considers the treatment, age and gender as covariates.

Countries

United States

Participant flow

Recruitment details

12clinical study sites in the US recruited 122 subjects that were randomized into the study. The date of first subject enrollment was 03 September 2015 and the date of last subject enrolled was 22 July 2016.

Pre-assignment details

Subject screening period was up to 14 days before receiving first study treatment. Subjects were contacted by an independent Massachusetts General Hospital-Clinical Trials Network and Institute (MGH-CTNI) rater to perform the Antidepressant Treatment Response Questionnaire (ATRQ) and SAFER assessments to confirm eligibility.

Participants by arm

ArmCount
LFMS Sham
For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. LFMS: Low field magnetic stimulation (1 kHz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
41
LFMS 20 Minutes
LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. LFMS: Low field magnetic stimulation (1 kHz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
40
LFMS 60 Minutes
LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. LFMS: Low field magnetic stimulation (1 kHz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
41
LFMS 120 Min
Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. LFMS: Low field magnetic stimulation (1 kHz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
0
Total122

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Follow-upSubject left town on Day 421000
Follow-upWithdrawal by Subject0001
Week 1 Initial RandommizationAdverse Event1000
Week 1 Initial RandommizationLost to Follow-up0010
Week 2 Stratification & Re-RandomizationLost to Follow-up2000
Week 2 Stratification & Re-RandomizationWithdrawal by Subject0002

Baseline characteristics

CharacteristicLFMS ShamLFMS 20 MinutesLFMS 60 MinutesLFMS 120 MinTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
4 Participants5 Participants4 Participants0 Participants13 Participants
Age, Categorical
Between 18 and 65 years
37 Participants35 Participants37 Participants0 Participants109 Participants
Race/Ethnicity, Customized
Asian
1 Participants3 Participants2 Participants0 Participants6 Participants
Race/Ethnicity, Customized
Black or African American
9 Participants9 Participants11 Participants0 Participants29 Participants
Race/Ethnicity, Customized
Other
0 Participants0 Participants1 Participants0 Participants1 Participants
Race/Ethnicity, Customized
White
31 Participants28 Participants27 Participants0 Participants86 Participants
Sex: Female, Male
Female
23 Participants23 Participants26 Participants0 Participants72 Participants
Sex: Female, Male
Male
18 Participants17 Participants15 Participants0 Participants50 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 790 / 400 / 410 / 41
other
Total, other adverse events
20 / 7914 / 4013 / 4110 / 41
serious
Total, serious adverse events
0 / 790 / 400 / 410 / 41

Outcome results

Primary

Change From Baseline to ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score.

Hamilton Rating Scales for Depression were designed to measure the severity of depressive symptoms in subjects with primary depressive illness. HAM-D6 is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 and all others are scored 0 to 4. Total score ranges from 0 to 22; higher score indicates more depression. Change from baseline: mean score at Week 1 Day 4 minus mean score at baseline. Week 1 Day 4 : Change from baseline to the end of the efficacy period ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) total score .Responders at Day 4 will be defined as those subjects who achieve a decrease in HAM-D6 total score of 50% or more compared to baseline (Day 1, Week 1). All other subjects will be deemed to be non-responders at Day 4. Each patient's total score is his/her own reference for determining a decrease of 50% or more.

Time frame: Week 1 Day 4

Population: Subjects in the All Randomized set who completed at least one treatment session and had at least one post baseline primary efficacy assessment.

ArmMeasureValue (LEAST_SQUARES_MEAN)
LFMS ShamChange From Baseline to ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score.-4.0 units on a scale
LFMS 20 MinutesChange From Baseline to ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score.-4.2 units on a scale
LFMS 60 MinutesChange From Baseline to ( Day 4) in the 6-item Hamilton Rating Scale for Depression (HAM-D6) Total Score.-4.9 units on a scale
Comparison: Comparisons of 60 min LFMS vs. sham, LSMean diff with 95% Confidence Interval (CI) reported. Hypothesis 1: no difference between 60 min. LFMS and sham therapy in mean change from baseline (Day 1) to end of Tx Day 4 in HAM-D6 total score. If hypothesis is rejected at significance level of 0.05, then second hypothesis will be tested. Hypothesis 2:no difference between 20 min. LFMS \& sham therapy in mean change from baseline (Day 1) to the end of Tx. Day 4 in HAM-D6 total score.p-value: 0.307Mixed Models Analysis
Comparison: Comparisons of 20 min LFMS vs. sham, LSMean diff with 95% Confidence Interval (CI) reported. Hypothesis 1: no difference between 60 min. LFMS and sham therapy in mean change from baseline (Day 1) to end of Tx Day 4 in HAM-D6 total score. If hypothesis is rejected at significance level of 0.05, then second hypothesis will be tested. Hypothesis 2:no difference between 20 min. LFMS \& sham therapy in mean change from baseline (Day 1) to the end of Tx. Day 4 in HAM-D6 total score.p-value: 0.859Mixed Models Analysis
Secondary

Change From Day 4 in HAM-D6 Total Score at Day 11 for Week 1 Non-responders: Response to 120 Minutes LFMS

Hamilton Rating Scales for Depression were designed to measure the severity of depressive symptoms in subjects with primary depressive illness. HAM-D6 is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 and all others are scored 0 to 4. Total score ranges from 0 to 22; higher score indicates more depression. Change from Day 11: mean score at Week 2 Day 11 minus mean score at Day 4. To determine if subjects with TRD who are non-responders to 0, 20 or 60 minutes of LFMS on Day 4 may respond to 120 minutes of LFMS at the end of Day 11. Responders will be defined as those subjects who achieve a decrease in HAM-D6 total score of 50% or more compared to baseline (Day 1, Week 1). All other subjects will be deemed to be non-responders. Each patient's total score is his/her own reference for determining a decrease of 50% or more.

Time frame: Day 11 (Week 2)

Population: Only non-responders at end of Day 4 comprise this Wk 2 analysis . (Non-responders were defined as those who didn't reach a decrease in 6-item Hamilton Rating Scale for Depression (HAM-D6) total score of 50% compared to baseline Day 1, Week 1). 41 subjects entered Week 2: 1 subject withdrew consent on Day 8 and was not part of the Full Analysis Set.

ArmMeasureValue (LEAST_SQUARES_MEAN)
LFMS ShamChange From Day 4 in HAM-D6 Total Score at Day 11 for Week 1 Non-responders: Response to 120 Minutes LFMS-2.6 units on a scale
LFMS 20 MinutesChange From Day 4 in HAM-D6 Total Score at Day 11 for Week 1 Non-responders: Response to 120 Minutes LFMS-2.6 units on a scale
p-value: 0.966Mixed Models Analysis
Secondary

Day 4 Responders: Persistence of Effect Based on Pre-specified HAM-D6 Total Score

To determine the persistence of response to LFMS therapy during a four-week follow-up period in subjects who were responders at Day 4. Persistence of response was achieved if during Week 2 post baseline visits and follow-up visits subjects' 6-item Hamilton Rating Scale for Depression (HAM-D6) total scores were lower than or equal to 50% of the baseline ( Day1 Week1) scores. Non-responder imputation method was used where missing post-baseline dichotomous (yes or no) were imputed as non-responder. Logistic regression model used to compare treatment groups for each visit, where the model considers the treatment, age and gender as covariates.

Time frame: Day 42

Population: Subjects who were HAM-D6 Day 4 responders, defined as those subjects who achieved a 50% or greater decrease in their HAM-D6 total score compared to Baseline ( Day1, Wk 1).

ArmMeasureValue (NUMBER)
LFMS ShamDay 4 Responders: Persistence of Effect Based on Pre-specified HAM-D6 Total Score53.8 percentage of LFMS responders
LFMS 20 MinutesDay 4 Responders: Persistence of Effect Based on Pre-specified HAM-D6 Total Score57.1 percentage of LFMS responders
LFMS 60 MinutesDay 4 Responders: Persistence of Effect Based on Pre-specified HAM-D6 Total Score78.6 percentage of LFMS responders
p-value: 0.294Regression, Logistic
p-value: 0.232Regression, Logistic
Post Hoc

Montgomery-Asberg Depression Rating Scale (MADRS): Change From Week 1 Baseline (Day 1) to End of Week 1 (Day 4)

The MADRS is a 10-item checklist designed to measure the overall severity of depressive symptoms in subjects with Major Depressive Disorder (MDD). Individual items are rated on a scale of 0 to 6 in which a score of 6 represents the most severe symptoms for each item assessed. The total score ranges from 0 to 60. Remission of depression based on the MADRS is defined as a subject with a MADRS total score of ≤11 at endpoint. A responder on the MADRS is defined as a 50% or greater reduction from baseline in total MADRS score

Time frame: Day 4 Week 1

Population: Full Analysis Set, Week1

ArmMeasureValue (LEAST_SQUARES_MEAN)
LFMS ShamMontgomery-Asberg Depression Rating Scale (MADRS): Change From Week 1 Baseline (Day 1) to End of Week 1 (Day 4)-7.58 units on a scale
LFMS 20 MinutesMontgomery-Asberg Depression Rating Scale (MADRS): Change From Week 1 Baseline (Day 1) to End of Week 1 (Day 4)-8.09 units on a scale
LFMS 60 MinutesMontgomery-Asberg Depression Rating Scale (MADRS): Change From Week 1 Baseline (Day 1) to End of Week 1 (Day 4)-10.32 units on a scale
Comparison: Estimates for LS Means, confidence intervals, difference in LS means and p-value are from an ANCOVA model with treatment, age, sex as factors and baseline negative MADRS score as a covariate.p-value: 0.0932ANCOVA
Comparison: Estimates for LS Means, confidence intervals, difference in LS means and p-value are from an ANCOVA model with treatment, age, sex as factors and baseline negative MADRS score as a covariate.p-value: 0.7509ANCOVA
Post Hoc

Positive and Negative Affect Schedule (PANAS): Change From Baseline at Day 4 in Positive Score

The PANAS comprises two mood scales, one that measures positive affect and the other that measures negative affect. Used as a psychometric scale, the PANAS can show relationships between positive and negative affect with personality stats and traits. Descriptors are used to define their meanings. Subjects completing the PANAS are required to respond to a 20-item test using 5-point scale that ranges from very slightly or not at all (1) to extremely (5).To calculate the positive affect score, added scores on items 1, 3, 5, 9, 10, 12, 14, 16, 17, and 19. Scores can range from 10-50, which higher scores representing higher levels of positive affect, or the extent to which the individual feels enthusiastic, active and alert.

Time frame: Day 4 Week 1

Population: Full Analysis Set (Week 1).

ArmMeasureValue (LEAST_SQUARES_MEAN)
LFMS ShamPositive and Negative Affect Schedule (PANAS): Change From Baseline at Day 4 in Positive Score1.67 units on a scale
LFMS 20 MinutesPositive and Negative Affect Schedule (PANAS): Change From Baseline at Day 4 in Positive Score3.62 units on a scale
LFMS 60 MinutesPositive and Negative Affect Schedule (PANAS): Change From Baseline at Day 4 in Positive Score3.24 units on a scale
p-value: 0.2672ANCOVA
p-value: 0.166ANCOVA
Post Hoc

Positive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at Day 4

The PANAS comprises two mood scales, one that measures positive affect and the other that measures negative affect. Subjects completing the PANAS are required to respond to a 20-item test using 5-point scale that ranges from very slightly or not at all (1) to extremely (5).Negative affect scores can be obtained by adding up scores for items 2, 4, 6, 7, 8, 11, 13, 15, 18 and 20. The negative affect score can range from 10 to 50, with lower scores representing lower level of negative affect, or the extent to which the individual feels aversive mood states and general distress. This analysis outcome treated Item #2 as random missing data.

Time frame: Day 4, Week 1

Population: Full analysis set, Week 1.Item #2 was incorrectly listed as Disinterested instead of Distressed.resulting in incorrect data for this item for the first 16 subjects. The PANAS data for the first 16 randomized subjects and in total 72 data points was identified and removed from the database. See stats analysis for further details.

ArmMeasureValue (LEAST_SQUARES_MEAN)
LFMS ShamPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at Day 4-2.27 units on a scale
LFMS 20 MinutesPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at Day 4-3.57 units on a scale
LFMS 60 MinutesPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at Day 4-5.32 units on a scale
Comparison: Due to item #2 error, analyses were done in the following manner to check robustness:~* All missing values including these 72 data points in item #2 were considered as random missing data (values posted in outcome measures).~* The 72 data points were removed \& the negative score for affected subjects \& visits were not calculated.~* The 72 data points were imputed using worst value imputation algorithm (using score =5 as extremely) while other random missing values imputed by average.p-value: 0.0307ANCOVA
Comparison: Due to item #2 error, analyses were done in the following manner to check robustness:~All missing values including these 72 data points in item #2 were considered as random missing data (values posted in outcome measures).~The 72 data points were removed \& the negative score for affected subjects \& visits were not calculated.~The 72 data points were imputed using worst value imputation algorithm (using score =5 as extremely) while other random missing values imputed by average.p-value: 0.3537ANCOVA
Post Hoc

Positive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at Day 4

The PANAS comprises two mood scales, one that measures positive affect and the other that measures negative affect. Subjects completing the PANAS are required to respond to a 20-item test using 5-point scale that ranges from very slightly or not at all (1) to extremely (5).Negative affect scores can be obtained by adding up scores for items 2, 4, 6, 7, 8, 11, 13, 15, 18 and 20. The negative affect score can range from 10 to 50, with lower scores representing lower level of negative affect, or the extent to which the individual feels aversive mood states and general distress. This analysis outcome treated Incorrect Item #2 where Item #2 data was removed.

Time frame: Day 4

Population: Full analysis set, Week 1.Item #2 was incorrectly listed as Disinterested instead of Distressed.resulting in incorrect data for this item for the first 16 subjects. The PANAS data for the first 16 randomized subjects and in total 72 data points was identified and removed from the database. See stats analysis for further details.

ArmMeasureValue (LEAST_SQUARES_MEAN)
LFMS ShamPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at Day 4-2.95 units on a scale
LFMS 20 MinutesPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at Day 4-3.78 units on a scale
LFMS 60 MinutesPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at Day 4-5.58 units on a scale
Comparison: Due to item #2 error, analyses were done in the following manner to check robustness:~All missing values including these 72 data points in item #2 were considered as random missing data (values posted in outcome measures).~The 72 data points were removed \& the negative score for affected subjects \& visits were not calculated.~The 72 data points were imputed using worst value imputation algorithm (using score =5 as extremely) while other random missing values imputed by average.p-value: 0.0848ANCOVA
Comparison: Due to item #2 error, analyses were done in the following manner to check robustness:~All missing values including these 72 data points in item #2 were considered as random missing data (values posted in outcome measures).~The 72 data points were removed \& the negative score for affected subjects \& visits were not calculated.~The 72 data points were imputed using worst value imputation algorithm (using score =5 as extremely) while other random missing values imputed by average.p-value: 0.593ANCOVA
Post Hoc

Positive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at End of Week 1, Day 4

The PANAS comprises two mood scales, one that measures positive affect and the other that measures negative affect. Subjects completing the PANAS are required to respond to a 20-item test using 5-point scale that ranges from very slightly or not at all (1) to extremely (5).Negative affect scores can be obtained by adding up scores for items 2, 4, 6, 7, 8, 11, 13, 15, 18 and 20. The negative affect score can range from 10 to 50, with lower scores representing lower level of negative affect, or the extent to which the individual feels aversive mood states and general distress. This analysis outcome approach took Incorrect Item #2 and imputed using worst possible value.

Time frame: Day 4, Week 1

Population: Full analysis set, Week 1.Item #2 was incorrectly listed as Disinterested instead of Distressed.resulting in incorrect data for this item for the first 16 subjects. The PANAS data for the first 16 randomized subjects and in total 72 data points was identified and removed from the database. See stats analysis for further details.

ArmMeasureValue (LEAST_SQUARES_MEAN)
LFMS ShamPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at End of Week 1, Day 4-2.29 units on a scale
LFMS 20 MinutesPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at End of Week 1, Day 4-3.50 units on a scale
LFMS 60 MinutesPositive and Negative Affect Schedule (PANAS) Change From Baseline in Negative Score at End of Week 1, Day 4-5.36 units on a scale
Comparison: Due to item #2 error, analyses were done in the following manner to check robustness:~All missing values including these 72 data points in item #2 were considered as random missing data (values posted in outcome measures).~The 72 data points were removed \& the negative score for affected subjects \& visits were not calculated.~The 72 data points were imputed using worst value imputation algorithm (using score =5 as extremely) while other random missing values imputed by average.p-value: 0.0307ANCOVA
Comparison: Due to item #2 error, analyses were done in the following manner to check robustness:~All missing values including these 72 data points in item #2 were considered as random missing data (values posted in outcome measures).~The 72 data points were removed \& the negative score for affected subjects \& visits were not calculated.~The 72 data points were imputed using worst value imputation algorithm (using score =5 as extremely) while other random missing values imputed by average.p-value: 0.3907ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026